Yes, Rinvoq (upadacitinib) is a medication that suppresses part of your immune system. The FDA classifies it as a JAK inhibitor, a type of drug that blocks specific enzymes your immune cells use to drive inflammation. While it’s not a broad immunosuppressant like steroids or methotrexate, the practical result is the same: your immune defenses are dialed down, which is why it works for inflammatory diseases and why it carries serious infection risks.
How Rinvoq Suppresses the Immune System
Your immune cells rely on a family of enzymes called JAK (Janus kinase) to relay signals from inflammatory molecules called cytokines. When a cytokine docks on a cell’s surface, JAK enzymes inside the cell activate a chain reaction that tells the cell to ramp up inflammation. Rinvoq blocks that chain reaction by competing for the spot where these enzymes get their energy, effectively cutting the signal before it reaches the cell’s nucleus.
Rinvoq is about 40 times more selective for JAK1 than JAK2, and over 100 times more selective for JAK1 than JAK3 or TYK2. This selectivity matters because different JAK enzymes control different immune functions. By primarily targeting JAK1, Rinvoq interrupts specific inflammatory pathways, particularly those driven by cytokines like IL-6 and IL-7, while leaving other immune signals less affected. That said, JAK enzymes work in pairs, so blocking JAK1 still has some downstream effects on other immune functions.
How It Differs From Broader Immunosuppressants
Traditional immunosuppressants like methotrexate, prednisone, azathioprine, and cyclosporine work by dampening the immune system more broadly. Methotrexate, for example, interferes with how rapidly dividing cells (including immune cells) replicate their DNA. This wide-reaching approach is why methotrexate commonly causes nausea, mouth sores, hair thinning, and liver toxicity, and why it achieves remission in only a minority of rheumatoid arthritis patients.
Rinvoq’s approach is more targeted, focusing on a specific signaling pathway rather than suppressing immune cell activity across the board. In practice, though, the distinction between “targeted immunosuppressant” and “broad immunosuppressant” doesn’t mean Rinvoq is safer overall. The FDA’s prescribing label explicitly warns against combining Rinvoq with potent immunosuppressants like azathioprine or cyclosporine, because stacking these effects can dangerously weaken your immune defenses. The label also warns against combining it with biologic immunomodulators.
Conditions Rinvoq Treats
The FDA has approved Rinvoq for a growing list of inflammatory conditions, all of which involve an overactive immune response. As of 2025, these include:
- Rheumatoid arthritis in adults
- Psoriatic arthritis in adults and children 2 and older
- Atopic dermatitis in adults and children 12 and older
- Ulcerative colitis in adults
- Crohn’s disease in adults
- Ankylosing spondylitis in adults
- Non-radiographic axial spondyloarthritis in adults
- Polyarticular juvenile idiopathic arthritis in patients 2 and older
- Giant cell arteritis in adults
For most of these conditions, Rinvoq is approved only after a patient has tried and failed (or couldn’t tolerate) TNF blockers, a different class of biologic therapy. It’s not typically a first-line treatment.
Infection Risks From Immune Suppression
Because Rinvoq reduces immune activity, infections are the most direct and common consequence. The FDA requires a boxed warning, its most serious safety alert, stating that patients on Rinvoq face increased risk of serious infections that can lead to hospitalization or death. These include tuberculosis, invasive fungal infections, and opportunistic viral and bacterial infections.
Shingles (herpes zoster) is a particularly notable risk with JAK inhibitors. In clinical trials covering over 27,000 patient-years of data, shingles occurred at a rate of 2.4 to 6.6 cases per 100 patient-years depending on the condition being treated. To put that in context, patients on Rinvoq developed shingles roughly 3 to 6 times more often than those taking adalimumab (a TNF blocker) or methotrexate. Higher doses of Rinvoq correlated with higher shingles rates, suggesting a dose-dependent relationship. Upper respiratory infections, urinary tract infections, and COVID-19 were also among the most frequently reported side effects.
Other Serious Safety Warnings
The boxed warning on Rinvoq covers five categories of risk, not just infections. A large postmarketing safety study of a different JAK inhibitor in rheumatoid arthritis patients over 50 with cardiovascular risk factors found higher rates of death (including sudden cardiovascular death), heart attacks, strokes, blood clots, and cancers compared to TNF blockers. Because these risks may apply to the entire drug class, the FDA extended similar warnings to Rinvoq.
Blood clots are a specific concern. Deep vein thrombosis, pulmonary embolism, and arterial clots have all occurred in patients taking Rinvoq, and some of these events were fatal. The cancer warning highlights higher rates of lymphoma and lung cancer seen with another JAK inhibitor. Current and former smokers face additional risk for both cardiovascular events and malignancies.
Blood Tests and Ongoing Monitoring
Because Rinvoq suppresses immune cell production and affects liver function and cholesterol, you’ll need regular blood work while taking it. Before starting, your doctor will check your white blood cell counts (specifically neutrophils and lymphocytes), hemoglobin levels, and liver enzymes. Treatment won’t be started, or will be paused, if your neutrophil count drops below 1,000 cells per cubic millimeter, your lymphocyte count falls below 500, or your hemoglobin drops below 8 g/dL.
Cholesterol levels are checked around 12 weeks after starting treatment, since JAK inhibitors can raise lipid levels. Liver enzymes are monitored on an ongoing basis, and if values climb in a way that suggests liver injury, treatment is paused until the cause is identified. The frequency of these tests after your initial baseline will depend on your individual situation.
How Quickly It Works
Rinvoq starts affecting your immune system after the first dose, but noticeable symptom improvement typically takes several weeks. This is faster than many traditional immunosuppressants like methotrexate, which can take two to three months to show full effects. The speed varies by condition and individual response, but if you’re several weeks in with no change, that’s worth discussing with your prescriber rather than assuming the drug isn’t working.